#United States #New York #Securities Class #GeneDx Holdings #SueWallSt

Investor Alert: GeneDx Holdings Corp. Securities Class Action

Investors in GeneDx Holdings Corp. (NASDAQ: WGS) need to take note of critical developments related to a securities class action lawsuit that could affect their investments. This lawsuit arises from statements made by GeneDx regarding its acquisition of Fabric Genomics, which has led to substantial financial implications for shareholders.

In a recent announcement, SueWallSt highlighted an important deadline for potential plaintiffs—August 3, 2026. This date marks the cutoff for investors who wish to be considered lead plaintiffs in this securities litigation. Those who bought shares during the class period of April 16, 2025, to May 4, 2026, may have the right to seek compensation for financial losses resulting from misleading statements by the company.

Background of the Case

The troubles for GeneDx began with its acquisition announcement for Fabric Genomics back on April 16, 2025. The company promised that Fabric would provide a recurring revenue-generating platform worth up to $51 million, sparking optimism among investors.

However, as time passed, reality set in. By May 5, 2026, shareholders witnessed a disturbing plunge in the stock price—from a high of $34.51 to a dramatic decline of approximately 49.20%, equivalent to a loss of $33.42 per share. This drop occurred after the company disclosed a substantial $31.2 million impairment charge linked to Fabric and drastically lowered its revenue guidance by $65 million, inflicting further losses on its investors.

Timeline of Key Events

It’s crucial to examine the timeline of events that led to this securities class action. Here are some significant milestones:

• - April 16, 2025: GeneDx announces the acquisition of Fabric Genomics, and the initial investor optimism begins.
• - May 5, 2025: The acquisition is finalized; management claims Fabric will unlock new revenue streams.
• - July 29, 2025: In its Q2 earnings call, the company expresses confidence in the merger and the future projections.
• - October 28, 2025: The Q3 call shows peak confidence with gross margins reported at 74%.
• - February 23, 2026: Early signs of trouble emerge as reimbursement rates for services decline.
• - May 4, 2026: The company reveals substantial financial misses, prompting a shocking stock drop and leading to the current class action.

What’s Next for WGS Investors?

For GeneDx shareholders affected by these developments, recovery options are available. Investors need to gather their brokerage records, documenting their purchase dates, amounts, and share prices. Even if you no longer own shares, you may still qualify for compensation if you bought during the class period.

Additionally, the role of the lead plaintiff is significant in class action lawsuits. The court selects a lead plaintiff based on documented losses, and this individual represents the entire class to ensure fair treatment. However, simply being a lead plaintiff does not guarantee higher recovery for individual shareholders but allows for oversight of the case’s management.

Contact for More Information

Investors interested in learning more about their rights and the ongoing legal process can contact SueWallSt, which operates under Levi Korsinsky LLP, a respected firm in securities litigation. They offer a no-cost consultation to provide insights into how you may be eligible for recovery.

In the face of the current economic climate and issues uncovered in GeneDx Holdings, it’s crucial that companies maintain transparency with their investors. As developments continue to evolve, affected shareholders must stay informed to ensure their legal rights are protected.

For further details, reach out via email at [email protected] or call (888) SueWallSt to explore your options regarding this pivotal lawsuit.